1. Home
  2. BGI vs NEUP Comparison

BGI vs NEUP Comparison

Compare BGI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birks Group Inc.

BGI

Birks Group Inc.

HOLD

Current Price

$1.04

Market Cap

22.7M

Sector

N/A

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.11

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGI
NEUP
Founded
1879
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
21.7M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
BGI
NEUP
Price
$1.04
$4.11
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
49.4K
55.2K
Earning Date
12-05-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,846,182.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.45
N/A
52 Week Low
$0.56
$3.00
52 Week High
$2.03
$21.40

Technical Indicators

Market Signals
Indicator
BGI
NEUP
Relative Strength Index (RSI) 60.70 48.99
Support Level $0.85 $4.01
Resistance Level $1.12 $4.43
Average True Range (ATR) 0.05 0.21
MACD 0.02 0.09
Stochastic Oscillator 69.98 64.10

Price Performance

Historical Comparison
BGI
NEUP

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: